- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02221700
Massageterapi til at reducere kemoterapi-induceret perifer neuropati hos patienter med gastrointestinale eller brystkræftsygdomme
En pilotundersøgelse af massage til symptomreduktion i kemoterapi-induceret perifer neuropati
This clinical trial studies massage therapy in reducing chemotherapy-induced nerve problems (peripheral neuropathy) that may cause pain, numbness, tingling, swelling, or muscle weakness in different parts of the body in patients with gastrointestinal or breast malignancies. Massage therapy may help reduce chemotherapy-induced peripheral neuropathy symptoms and improve quality of life.
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
PRIMARY OBJECTIVES; I. To compare completion rates of two massage treatment protocols (twice-weekly for 6 weeks versus three times weekly for 4 weeks) for patients with chronic, chemotherapy-induced peripheral neuropathy.
SECONDARY OBJECTIVES:
I. To determine the initial efficacy and effect size estimates of twice versus three times weekly site specific (lower extremity) massage versus alternate massage site (head/neck/shoulder) control groups at treating chronic, lower extremity chemotherapy-induced peripheral neuropathy.
II. To determine the initial efficacy and effect size estimates of massage on patient quality of life and functional performance tests.
OUTLINE: Patients are randomized to 1 of 4 groups.
GROUP I: Patients undergo massage therapy over 30 minutes to the affected legs at the foot and toes, ending at the knee, thrice weekly for 4 weeks.
GROUP II: Patients undergo massage therapy over 30 minutes to the affected legs at the foot and toes, ending at the knee, twice weekly for 6 weeks.
GROUP III: Patients undergo massage therapy over 30 minutes to the head, neck, and shoulder thrice weekly for 4 weeks.
GROUP IV: Patients undergo massage therapy over 30 minutes to the head, neck, and shoulder twice weekly for 6 weeks.
After completion of study, patients are followed periodically.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- M D Anderson Cancer Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
All gastrointestinal malignancies where the patient received oxaliplatin for cancer treatment or breast malignancies where patients have received docetaxel or paclitaxel for cancer treatment
-
Greater or equal to 6 months from last chemotherapy treatment
-
Must understand and read English, sign a written informed consent, and follow protocol requirements
-
Must be willing to come to MD Anderson Main Campus (Texas Medical Center) for intervention
-
Lower extremity neuropathy per patient report attributable to oxaliplatin, docetaxel or paclitaxel (neurotoxic chemotherapeutic agent) as determined by patient history of neurotoxic agent administration and no history of other attributable causes such as diabetic neuropathy
-
Patient self-report neuropathy score greater than or equal to 3 on a 0 to 10 numeric scale and/or grade 2 or 3 neuropathy (according to the National Cancer Institute Common Toxicity Criteria 4 point grading scale)
-
Within 2 weeks prior to study enrollment the patient must be on a stable dose of medications for management of chemotherapy-induced peripheral neuropathy (CIPN) symptoms; for at least 2 weeks prior to enrollment stable dose is defined as:
- No change in drug class
- Increases or decreases that are less than or equal to 20% of the total dosage; all drug classes are allowed
Exclusion Criteria:
- Patients with previously diagnosed peripheral neuropathy pre-dating their neurotoxic chemotherapy administration or from causes other than chemotherapy
- Platelets less than 50,000 within 6 months prior to study enrollment or
- Neutrophil count less than 500 within 6 months prior to study enrollment
- Deep venous thrombosis (DVT) diagnosed within 12 months of study enrollment or history or untreated lower extremity DVT, bone metastases, currently active skin infection, or lymphedema currently involving the treatment field
- Women who are pregnant at time of enrollment; pregnancy will be assessed at enrollment using urine pregnancy test
- Diagnosis of diabetes
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Group I (leg massage 3 x weekly for 4 weeks)
Patients undergo massage therapy over 30 minutes to the affected legs at the foot and toes, ending at the knee, thrice weekly for 4 weeks. |
Ancillary studies
Andre navne:
Ancillary studies Undergo massage therapy
Andre navne:
|
|
Eksperimentel: Group II (leg massage 2 x weekly for 6 weeks)
Patients undergo massage therapy over 30 minutes to the affected legs at the foot and toes, ending at the knee, twice weekly for 6 weeks. |
Ancillary studies
Andre navne:
Ancillary studies Undergo massage therapy
Andre navne:
|
|
Eksperimentel: Group III (head/neck/shoulder massage 3 x weekly for 4 weeks)
Patients undergo massage therapy over 30 minutes to the head, neck, and shoulder thrice weekly for 4 weeks. |
Ancillary studies
Andre navne:
Ancillary studies Undergo massage therapy
Andre navne:
|
|
Eksperimentel: Group IV (head/neck/shoulder massage 2 x weekly for 6 weeks)
Patients undergo massage therapy over 30 minutes to the head, neck, and shoulder twice weekly for 6 weeks. |
Ancillary studies
Andre navne:
Ancillary studies Undergo massage therapy
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Completion Rates of Two Massage Treatment Protocols for Patients With Chronic, Oxaliplatin-Induced Peripheral Neuropathy
Tidsramme: 10 weeks
|
Completion rate defined as the average number of treatments completed of a possible 12 for patients in each protocol. Mean and standard deviation, along with a 95% confidence interval (CI) of the mean of the number of massages completed for each of the two massage schedules computed. Two-sample t-test used to compare the number of massages completed between the two schedules using a two-sided 0.05 significance level. |
10 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Quality and intensity of neuropathic pain
Tidsramme: At 10 weeks
|
Will be measured by Pain Quality Assessment Scale (PQAS). To estimate the efficacy of the massage treatments at 10 weeks, linear regression will be used with PQAS as the dependent variable, massage site and schedule being two binary independent variables with interaction, adjusting for appropriate covariates such as the baseline value of PQAS. To assess the efficacy of the massage treatments over time linear mixed models (LMMs) will be used. |
At 10 weeks
|
|
Quality of life (QOL)
Tidsramme: Up to 10 weeks
|
Will be measured by the Medical Outcomes Study Short Form 36. Pairwise comparisons between arms will be made as desirable, adjusting for multiple comparisons using the Bonferroni approach. Similar linear regression and LMM analyses will be carried out for the QOL and function measures. |
Up to 10 weeks
|
|
Function and balance
Tidsramme: Up to 10 weeks
|
Will be measured by the Timed Up and Go test, the Single Limb Stance, and the Activities-Specific Balance Confidence Scale. Pairwise comparisons between arms will be made as desirable, adjusting for multiple comparisons using the Bonferroni approach. Similar linear regression and LMM analyses will be carried out for the QOL and function measures. |
Up to 10 weeks
|
|
Symptoms associated specifically with chemotherapy-induced peripheral neuropathy
Tidsramme: Up to 10 weeks
|
Will be assessed using the Functional Assessment of Cancer Therapy/Gynecological Oncology Group-neurotoxicity version 4 questionnaire. Pairwise comparisons between arms will be made as desirable, adjusting for multiple comparisons using the Bonferroni approach. Similar linear regression and LMM analyses will be carried out for the QOL and function measures. |
Up to 10 weeks
|
|
Baseline treatment expectations
Tidsramme: Baseline
|
Baseline treatment expectations will be assessed as a predictor of the secondary measures at week 10. |
Baseline
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Gabriel Lopez, M.D. Anderson Cancer Center
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Anslået)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i nervesystemet
- Neoplasmer efter sted
- Neoplasmer
- Neuromuskulære sygdomme
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Hudsygdomme
- Brystsygdomme
- Hud- og bindevævssygdomme
- Brystneoplasmer
- Gastrointestinale neoplasmer
- Sygdomme i det perifere nervesystem
- Terapeutik
- Komplementære terapier
- Fysioterapimodaliteter
- Rehabilitering
- Terapi, blødt væv
- Muskuloskeletale manipulationer
- Massage
Andre undersøgelses-id-numre
- 2014-0250
- 2014-0250 (Anden identifikator: M D Anderson Cancer Center)
- NCI-2015-00386 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .